Spironolactone and eplerenone were without effect on infarct size in female SHRSP despite a higher relative expression of MR in cerebral arteries in females than males[45], highlighting a potential sex difference in the utility of MR antagonists for stroke therapy. The gene discussed is NR3C2; the disease is stroke disorder.